# Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

> **NCT00094146** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 160 (—)

## Conditions studied

- Primary Insulin Hypersecretion
- Obesity

## Interventions

- **DRUG:** Sandostatin LAR Depot

## Key facts

- **NCT ID:** NCT00094146
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** —
- **Final completion:** 2002-12
- **Target enrollment:** 160 (—)
- **Last updated:** 2009-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094146, "Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00094146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*